A Phase 2 Multicenter, Double-blind, Randomized, Adjunctive, Placebo-controlled Trial With an Open-label Extension to Evaluate the Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Nov 2017
At a glance
- Drugs Cenobamate (Primary)
- Indications Partial epilepsies
- Focus Therapeutic Use
- Sponsors SK Life Science
- 30 Oct 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 21 Sep 2016 Status changed from completed to active, no longer recruiting.
- 21 Sep 2016 Planned End Date changed from 1 Jul 2013 to 1 Dec 2018.